Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Impact of Patient-Provider Attachment on Hospital Readmissions Among People Living With HIV: A Population-Based Study.

Parent S, Barrios R, Nosyk B, Ye M, Bacani N, Panagiotoglou D, Montaner J, Ti L.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):551-558. doi: 10.1097/QAI.0000000000001857.

PMID:
30204719
2.

The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study.

Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, Rafful C, Morales M, Cepeda J, Panagiotoglou D, Krebs E, Vickerman P, Claude Boily M, Thomson N, Martin NK.

Lancet Public Health. 2018 Sep;3(9):e429-e437. doi: 10.1016/S2468-2667(18)30097-5. Epub 2018 Aug 17.

3.

Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver's Downtown Eastside.

Olding M, Hayashi K, Pearce L, Bingham B, Buchholz M, Gregg D, Hamm D, Shaver L, McKendry R, Barrios R, Nosyk B.

Int J Drug Policy. 2018 Sep;59:16-23. doi: 10.1016/j.drugpo.2018.06.003. Epub 2018 Jun 29.

PMID:
29966804
4.

Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities.

Panagiotoglou D, Olding M, Enns B, Feaster DJ, Del Rio C, Metsch LR, Granich RM, Strathdee SA, Marshall BDL, Golden MR, Shoptaw S, Schackman BR, Nosyk B; Localized HIV Modeling Study Group.

AIDS Behav. 2018 Sep;22(9):3071-3082. doi: 10.1007/s10461-018-2166-6.

PMID:
29802550
5.

Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada.

Eyawo O, Hull MW, Salters K, Samji H, Cescon A, Sereda P, Lima VD, Nosyk B, Whitehurst DGT, Lear SA, Montaner JSG, Hogg RS; Comparative Outcomes And Service Utilization Trends (COAST) Study.

BMJ Open. 2018 Jan 13;8(1):e019115. doi: 10.1136/bmjopen-2017-019115.

6.

Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.

Krebs E, Enns B, Evans E, Urada D, Anglin MD, Rawson RA, Hser YI, Nosyk B.

Ann Intern Med. 2018 Jan 2;168(1):10-19. doi: 10.7326/M17-0611. Epub 2017 Nov 21.

PMID:
29159398
7.

Progress towards the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, Canada.

Lima VD, St-Jean M, Rozada I, Shoveller JA, Nosyk B, Hogg RS, Sereda P, Barrios R, Montaner JSG.

J Int AIDS Soc. 2017 Nov;20(3). doi: 10.1002/jia2.25011.

8.

Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015.

Wang L, Min JE, Zang X, Sereda P, Harrigan RP, Montaner JSG, Nosyk B.

Clin Infect Dis. 2017 Oct 16;65(9):1496-1503. doi: 10.1093/cid/cix570.

9.

The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013.

Nosyk B, Min JE, Krebs E, Zang X, Compton M, Gustafson R, Barrios R, Montaner JSG; STOP HIV/AIDS Study Group .

Clin Infect Dis. 2018 Feb 10;66(5):765-777. doi: 10.1093/cid/cix832.

PMID:
29028964
10.

A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015.

Olding M, Enns B, Panagiotoglou D, Shoveller J, Harrigan PR, Barrios R, Kerr T, Montaner JSG, Nosyk B.

J Int AIDS Soc. 2017 Sep 19;20(1):21941. doi: 10.7448/IAS.20.1.21941. Review.

11.

The costs of crime associated with stimulant use in a Canadian setting.

Enns B, Krebs E, DeBeck K, Hayashi K, Milloy MJ, Richardson L, Wood E, Nosyk B.

Drug Alcohol Depend. 2017 Nov 1;180:304-310. doi: 10.1016/j.drugalcdep.2017.08.026. Epub 2017 Sep 14.

12.

Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users.

Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, Hser YI, Nosyk B.

Int J Drug Policy. 2017 Nov;49:32-40. doi: 10.1016/j.drugpo.2017.07.009. Epub 2017 Sep 6.

13.

Informing Targeted Interventions to Optimize the Cascade of HIV Care Using Cluster Analyses of Health Resource Use Among People Living with HIV/AIDS.

Krebs E, Min JE, Bayoumi AM, Barrios R, Montaner JSG, Nosyk B; STOP HIV/AIDS Study Group.

AIDS Behav. 2018 Jan;22(1):234-244. doi: 10.1007/s10461-017-1839-x.

PMID:
28660380
14.

Hepatitis C testing in Canada: don't leave baby boomers behind.

Ti L, Lima V, Hull M, Nosyk B, Joy J, Montaner J, Krajden M, Harrigan R, Kerr T, Shannon K, Wood E, Shoveller J, Ramji A, Ko HH, Yoshida E, Hall D, Barrios R.

CMAJ. 2017 Jun 26;189(25):E870-E871. doi: 10.1503/cmaj.733111. No abstract available.

15.

Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?

Panagiotoglou D, Krebs E, Min JE, Olding M, Ahamad K, Ti L, Montaner JSG, Nosyk B.

Int J Drug Policy. 2017 Sep;47:169-176. doi: 10.1016/j.drugpo.2017.05.021. Epub 2017 Jun 1.

16.

Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.

Nosyk B, Zang X, Min JE, Krebs E, Lima VD, Milloy MJ, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E, Montaner JSG.

Lancet HIV. 2017 Jul;4(7):e303-e310. doi: 10.1016/S2352-3018(17)30045-0. Epub 2017 Mar 30.

17.

Joint Utility Estimators in Substance Use Disorders.

Wittenberg E, Bray JW, Gebremariam A, Aden B, Nosyk B, Schackman BR.

Value Health. 2017 Mar;20(3):458-465. doi: 10.1016/j.jval.2016.09.2404. Epub 2016 Nov 17.

18.

Quality of life as an outcome of opioid use disorder treatment: A systematic review.

Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, Stribling JC, Schackman BR.

J Subst Abuse Treat. 2017 May;76:88-93. doi: 10.1016/j.jsat.2017.01.019. Epub 2017 Feb 10. Review.

19.

Estimating State Transitions for Opioid Use Disorders.

Krebs E, Min JE, Evans E, Li L, Liu L, Huang D, Urada D, Kerr T, Hser YI, Nosyk B.

Med Decis Making. 2017 Jul;37(5):483-497. doi: 10.1177/0272989X16683928. Epub 2016 Dec 27.

20.

The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B.

Addiction. 2017 May;112(5):838-851. doi: 10.1111/add.13729. Epub 2017 Feb 6.

21.

Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.

Zang X, Tang H, Min JE, Gu D, Montaner JS, Wu Z, Nosyk B.

PLoS One. 2016 Nov 28;11(11):e0167308. doi: 10.1371/journal.pone.0167308. eCollection 2016.

22.

Increased drug use and the timing of social assistance receipt among people who use illicit drugs.

Krebs E, Wang L, Olding M, DeBeck K, Hayashi K, Milloy MJ, Wood E, Nosyk B, Richardson L.

Soc Sci Med. 2016 Dec;171:94-102. doi: 10.1016/j.socscimed.2016.11.006. Epub 2016 Nov 4.

23.

Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting.

Wang L, Panagiotoglou D, Min JE, DeBeck K, Milloy MJ, Kerr T, Hayashi K, Nosyk B.

Drug Alcohol Depend. 2016 Nov 1;168:22-29. doi: 10.1016/j.drugalcdep.2016.08.631. Epub 2016 Sep 1.

24.

Protocol of the impact of alternative social assistance disbursement on drug-related harm (TASA) study: a randomized controlled trial to evaluate changes to payment timing and frequency among people who use illicit drugs.

Richardson L, Laing A, Milloy MJ, Maynard R, Nosyk B, Marshall B, Grafstein E, Daly P, Wood E, Montaner J, Kerr T.

BMC Public Health. 2016 Jul 29;16:668. doi: 10.1186/s12889-016-3304-6.

25.

Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder.

Krebs E, Kerr T, Wood E, Nosyk B.

J Subst Abuse Treat. 2016 Aug;67:30-7. doi: 10.1016/j.jsat.2016.05.001. Epub 2016 May 9.

26.

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, Krajden M, Yoshida E, Wood E, Montaner JS.

PLoS One. 2015 Dec 3;10(12):e0143836. doi: 10.1371/journal.pone.0143836. eCollection 2015.

27.

Short term health-related quality of life improvement during opioid agonist treatment.

Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, Schackman BR.

Drug Alcohol Depend. 2015 Dec 1;157:121-8. doi: 10.1016/j.drugalcdep.2015.10.009. Epub 2015 Oct 25.

28.

Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.

Wittenberg E, Bray JW, Aden B, Gebremariam A, Nosyk B, Schackman BR.

Addiction. 2016 Apr;111(4):675-84. doi: 10.1111/add.13219. Epub 2015 Dec 17.

29.

Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.

Nosyk B, Min JE, Lima VD, Hogg RS, Montaner JS; STOP HIV/AIDS study group.

Lancet HIV. 2015 Sep;2(9):e393-400. doi: 10.1016/S2352-3018(15)00127-7. Epub 2015 Jul 16.

30.

The need for standardisation of the HIV continuum of care.

Lourenço L, Hull M, Nosyk B, Montaner JS, Lima VD.

Lancet HIV. 2015 Jun;2(6):e225-6. doi: 10.1016/S2352-3018(15)00086-7. Epub 2015 May 27. No abstract available.

31.

Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'.

Nosyk B, Lourenço L, Min JE, Shopin D, Lima VD, Montaner JS; STOP HIVAIDS Study Group.

AIDS. 2015 Aug 24;29(13):1681-9. doi: 10.1097/QAD.0000000000000746.

32.

The 'Expanded HIV care in opioid substitution treatment' (EHOST) cluster-randomized, stepped-wedge trial: A study protocol.

Nosyk B, Krebs E, Min JE, Ahamad K, Buxton J, Goldsmith C, Hull M, Joe R, Krajden M, Lima VD, Olding M, Wood E, Montaner JSG.

Contemp Clin Trials. 2015 Nov;45(Pt B):201-209. doi: 10.1016/j.cct.2015.08.020. Epub 2015 Sep 3.

PMID:
26342295
33.

Gender differences in mortality among treated opioid dependent patients.

Evans E, Kelleghan A, Li L, Min J, Huang D, Urada D, Hser YI, Nosyk B.

Drug Alcohol Depend. 2015 Oct 1;155:228-35. doi: 10.1016/j.drugalcdep.2015.07.010. Epub 2015 Jul 17.

34.

Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment.

Aden B, Dunning A, Nosyk B, Wittenberg E, Bray JW, Schackman BR.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):304-10. doi: 10.1097/QAI.0000000000000768.

35.

Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care.

Lourenço L, Nohpal A, Shopin D, Colley G, Nosyk B, Montaner JS, Lima VD; Seek and Treat for Optimal Prevention of HIV/AIDS Study Group.

HIV Med. 2016 Apr;17(4):269-79. doi: 10.1111/hiv.12297. Epub 2015 Jul 28.

36.

The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs.

Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JS.

Clin Infect Dis. 2015 Oct 1;61(7):1157-65. doi: 10.1093/cid/civ476. Epub 2015 Jun 25.

37.

The causal effect of opioid substitution treatment on HAART medication refill adherence.

Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJ, Wood E, Montaner JS.

AIDS. 2015 May 15;29(8):965-73. doi: 10.1097/QAD.0000000000000642.

38.

The rise of marijuana and the fall of cocaine in the United States: for better, for worse?

Nosyk B, Wood E, Kerr T.

Addiction. 2015 May;110(5):737-8. doi: 10.1111/add.12738. No abstract available.

PMID:
25868537
39.

Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.

Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B.

Addiction. 2015 Jun;110(6):996-1005. doi: 10.1111/add.12863. Epub 2015 Mar 15.

40.

High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada.

Lourenço L, Colley G, Nosyk B, Shopin D, Montaner JS, Lima VD; STOP HIV/AIDS Study Group.

PLoS One. 2014 Dec 26;9(12):e115277. doi: 10.1371/journal.pone.0115277. eCollection 2014.

41.

Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study.

Nosyk B, Lima V, Colley G, Yip B, Hogg RS, Montaner JS.

Pharmacoeconomics. 2015 Mar;33(3):243-53. doi: 10.1007/s40273-014-0229-8.

42.

Dynamics in the costs of criminality among opioid dependent individuals.

Krebs E, Kerr T, Montaner J, Wood E, Nosyk B.

Drug Alcohol Depend. 2014 Nov 1;144:193-200. doi: 10.1016/j.drugalcdep.2014.09.007. Epub 2014 Sep 22.

43.

Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?

Nosyk B, Krebs E, Eyawo O, Min JE, Barrios R, Montaner JS.

Curr HIV/AIDS Rep. 2014 Dec;11(4):468-78. doi: 10.1007/s11904-014-0227-7. Review.

PMID:
25173799
44.

Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012.

Nosyk B, Li L, Evans E, Urada D, Huang D, Wood E, Rawson R, Hser YI.

Drug Alcohol Depend. 2014 Oct 1;143:149-57. doi: 10.1016/j.drugalcdep.2014.07.020. Epub 2014 Jul 27.

45.

Process monitoring of an HIV treatment as prevention program in British Columbia, Canada.

Lourenço L, Lima VD, Heath K, Nosyk B, Gilbert M, Colley G, Consolacion T, Barrios R, Hogg R, Krajden M, Konrad S, Murti M, Nelson J, May-Hadford J, Haggerstone J, Pick N, Gustafson R, Rusch M, Day I, Montaner JS; STOP HIV/AIDS Study Group.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):e94-e109. doi: 10.1097/QAI.0000000000000293.

46.

Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.

Nosyk B, Montaner JS, Yip B, Lima VD, Hogg RS; STOP HIVAIDS Study Group.

Med Care. 2014 Apr;52(4):362-9. doi: 10.1097/MLR.0000000000000097.

47.

Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users.

Nosyk B, Li L, Evans E, Huang D, Min J, Kerr T, Brecht ML, Hser YI.

Drug Alcohol Depend. 2014 Jul 1;140:69-77. doi: 10.1016/j.drugalcdep.2014.03.029. Epub 2014 Apr 8.

48.

High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: results from a population-level retrospective cohort study.

Nosyk B, Fischer B, Sun H, Marsh DC, Kerr T, Rehm JT, Anis AH.

Am J Addict. 2014 May-Jun;23(3):257-64. doi: 10.1111/j.1521-0391.2014.12091.x.

49.

Cohort profile: Seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC).

Heath K, Samji H, Nosyk B, Colley G, Gilbert M, Hogg RS, Montaner JS; STOP HIV/AIDS Study Group.

Int J Epidemiol. 2014 Aug;43(4):1073-81. doi: 10.1093/ije/dyu070. Epub 2014 Apr 2.

50.

Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.

Patterson S, Cescon A, Samji H, Cui Z, Yip B, Lepik KJ, Moore D, Lima VD, Nosyk B, Harrigan PR, Montaner JS, Shannon K, Wood E, Hogg RS.

Int J Epidemiol. 2015 Feb;44(1):58-67. doi: 10.1093/ije/dyu046. Epub 2014 Mar 17.

Supplemental Content

Support Center